Heart failure & cardiomyopathies
Effects of Sacubitril/Valsartan vs Valsartan in De Novo vs Acute on Chronic HFpEF and HFmrEF
Authors' conclusion
There is no interaction between HF chronicity and the effect of sacubitril-valsartan.
Study context
- Population
- Patients with EF >40% stabilized after worsening heart failure (HF), classified as de novo (first HF diagnosis) or chronic (known HF before index event)153 de novo, 313 chronic HF
- Participants
- 466 patients
- Comparison
- Sacubitril/valsartan vs valsartan, by de novo vs chronic HF
- Primary endpoint
- Time-averaged proportional change in NT-proBNP
- Follow-up
- Baseline to weeks 4 and 8
Methodological detailsprespecified analysis
- Prespecified analysis
Primary result
As reported in the abstract
NT-proBNP change, by HF chronicity (subgroup) · weeks 4 and 8
De novo HF
0.82
95% CI 0.62–1.07
Chronic HF
0.88
95% CI 0.73–1.07
Further findings
| Outcome | Win ratio (95% CI) | |
|---|---|---|
| Win ratio (CV death, HF hospitalizations, urgent HF visits, NT-proBNP change), by HF chronicitySacubitril/valsartanvs ValsartanDe novo HF · nominally in favour of sacubitril/valsartan | 1.12 (0.70–1.58) | |
| Win ratio (CV death, HF hospitalizations, urgent HF visits, NT-proBNP change), by HF chronicitySacubitril/valsartanvs ValsartanChronic HF · nominally in favour of sacubitril/valsartan | 1.24 (0.89–1.71) | |
| 0.512Win ratio (log scale) |
Baseline characteristics, de novo vs chronic HF
- De novo patients had lower rates of AF/flutter and lower creatinine
Original publication
Effects of Sacubitril/Valsartan vs Valsartan in De Novo vs Acute on Chronic HFpEF and HFmrEF. JACC Adv. Published 14 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →